117 related articles for article (PubMed ID: 23499651)
21. Activity of glutaraldehyde at low concentrations against capsid proteins of poliovirus type 1 and echovirus type 25.
Chambon M; Bailly JL; Peigue-Lafeuille H
Appl Environ Microbiol; 1992 Nov; 58(11):3517-21. PubMed ID: 1336351
[TBL] [Abstract][Full Text] [Related]
22. Isolation of recombinant type 2 vaccine-derived poliovirus (VDPV) from a Nigerian child.
Adu F; Iber J; Bukbuk D; Gumede N; Yang SJ; Jorba J; Campagnoli R; Sule WF; Yang CF; Burns C; Pallansch M; Harry T; Kew O
Virus Res; 2007 Jul; 127(1):17-25. PubMed ID: 17449127
[TBL] [Abstract][Full Text] [Related]
23. Isolation of a type 3 vaccine-derived poliovirus (VDPV) from an Iranian child with X-linked agammaglobulinemia.
Shahmahmoodi S; Parvaneh N; Burns C; Asghar H; Mamishi S; Tabatabaie H; Chen Q; Teimourian S; Gooya MM; Esteghamati AR; Mousavi T; Yousefi M; Farrokhi K; Mashlool M; Kew O; Nategh R
Virus Res; 2008 Oct; 137(1):168-72. PubMed ID: 18674576
[TBL] [Abstract][Full Text] [Related]
24. Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design.
Grant RA; Hiremath CN; Filman DJ; Syed R; Andries K; Hogle JM
Curr Biol; 1994 Sep; 4(9):784-97. PubMed ID: 7820548
[TBL] [Abstract][Full Text] [Related]
25. In vitro antiviral activity of V-073 against polioviruses.
Oberste MS; Moore D; Anderson B; Pallansch MA; Pevear DC; Collett MS
Antimicrob Agents Chemother; 2009 Oct; 53(10):4501-3. PubMed ID: 19635956
[TBL] [Abstract][Full Text] [Related]
26. Insights into the genetic basis for natural phenotypic resistance of human rhinoviruses to pleconaril.
Ledford RM; Collett MS; Pevear DC
Antiviral Res; 2005 Dec; 68(3):135-8. PubMed ID: 16199099
[TBL] [Abstract][Full Text] [Related]
27. Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VP0, VP3, and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein.
Bräutigam S; Snezhkov E; Bishop DH
Virology; 1993 Feb; 192(2):512-24. PubMed ID: 8380663
[TBL] [Abstract][Full Text] [Related]
28. Retrospective characterization of a vaccine-derived poliovirus type 1 isolate from sewage in Greece.
Dedepsidis E; Kyriakopoulou Z; Pliaka V; Kottaridi C; Bolanaki E; Levidiotou-Stefanou S; Komiotis D; Markoulatos P
Appl Environ Microbiol; 2007 Nov; 73(21):6697-704. PubMed ID: 17827314
[TBL] [Abstract][Full Text] [Related]
29. In vitro antiviral activity of single domain antibody fragments against poliovirus.
Thys B; Schotte L; Muyldermans S; Wernery U; Hassanzadeh-Ghassabeh G; Rombaut B
Antiviral Res; 2010 Aug; 87(2):257-64. PubMed ID: 20566349
[TBL] [Abstract][Full Text] [Related]
30. Detection of MEF-1 laboratory reference strain of poliovirus type 2 in children with poliomyelitis in India in 2002 & 2003.
Deshpande JM; Nadkarni SS; Siddiqui ZA
Indian J Med Res; 2003 Dec; 118():217-23. PubMed ID: 14870793
[TBL] [Abstract][Full Text] [Related]
31. Characterization of Poliovirus Neutralization Escape Mutants of Single-Domain Antibody Fragments (VHHs).
Schotte L; Thys B; Strauss M; Filman DJ; Rombaut B; Hogle JM
Antimicrob Agents Chemother; 2015 Aug; 59(8):4695-706. PubMed ID: 26014941
[TBL] [Abstract][Full Text] [Related]
32. An antiviral compound that blocks structural transitions of poliovirus prevents receptor binding at low temperatures.
Dove AW; Racaniello VR
J Virol; 2000 Apr; 74(8):3929-31. PubMed ID: 10729171
[TBL] [Abstract][Full Text] [Related]
33. Characterization of mutations in the VP(1) region of Sabin strain type 1 polioviruses isolated from vaccine-associated paralytic poliomyelitis cases in Iran.
Rahimi P; Tabatabaie H; Gouya MM; Zahraie M; Mahmudi M; Ziaie A; Rad KS; Shahmahmudi Sh; Musavi T; Azad TM; Nategh R
J Clin Virol; 2007 Aug; 39(4):304-7. PubMed ID: 17590391
[TBL] [Abstract][Full Text] [Related]
34. Viral therapy: prospects for protease inhibitors.
Korant BD; Towatari T; Ivanoff L; Petteway S; Brzin J; Lenarcic B; Turk V
J Cell Biochem; 1986; 32(2):91-5. PubMed ID: 3023407
[TBL] [Abstract][Full Text] [Related]
35. In vitro antiviral activity of the anthraquinone chrysophanic acid against poliovirus.
Semple SJ; Pyke SM; Reynolds GD; Flower RL
Antiviral Res; 2001 Mar; 49(3):169-78. PubMed ID: 11428243
[TBL] [Abstract][Full Text] [Related]
36. One amino acid change on the capsid surface of poliovirus sabin 1 allows the establishment of persistent infections in HEp-2c cell cultures.
Pelletier I; Duncan G; Colbère-Garapin F
Virology; 1998 Feb; 241(1):1-13. PubMed ID: 9454712
[TBL] [Abstract][Full Text] [Related]
37. [Genetic variability of Poliovirus: typing of strains isolated in Madagascar by restriction fragment length polymorphism (RFLP) assay].
Razafindratsimandresy R; Rakoto Andrianarivelo M; Rousset D
Arch Inst Pasteur Madagascar; 2003; 69(1-2):27-32. PubMed ID: 15678812
[TBL] [Abstract][Full Text] [Related]
38. Isolation of a recombinant type 3/type 2 poliovirus with a chimeric capsid VP1 from sewage in Shandong, China.
Tao Z; Wang H; Xu A; Zhang Y; Song L; Zhu S; Li Y; Yan D; Liu G; Yoshida H; Liu Y; Feng L; Chosa T; Xu W
Virus Res; 2010 Jun; 150(1-2):56-60. PubMed ID: 20206214
[TBL] [Abstract][Full Text] [Related]
39. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor.
Binford SL; Maldonado F; Brothers MA; Weady PT; Zalman LS; Meador JW; Matthews DA; Patick AK
Antimicrob Agents Chemother; 2005 Feb; 49(2):619-26. PubMed ID: 15673742
[TBL] [Abstract][Full Text] [Related]
40. Type 2 poliovirus recombinants isolated from vaccine-associated cases and from healthy contacts in Brazil.
Friedrich F; Da-Silva EF; Schatzmayr HG
Acta Virol; 1996 Feb; 40(1):27-33. PubMed ID: 8886095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
